Evidence map›Paper›PMID 38265519›Full record

ArticleInternational journal of clinical pharmacy2024

Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.

Mansour Tobaiqy, Hajer Elkout

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical pharmacy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 7 pooled it
25.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 7 syntheses or guidelines pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Association of Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Mansour TobaiqyDepartment of Pharmacology, College of Medicine, University of Jeddah, Jeddah, Saudi Arabia. mtobaiqy@uj.edu.sa.ORCID http://orcid.org/0000-0002-4292-0900
Hajer ElkoutDepartment of Family and Community Medicine, Medical Faculty, University of Tripoli, Tripoli, 13275, Libya.ORCID http://orcid.org/0000-0003-3191-3868
University of Jeddah · SAUniversity of Tripoli · LY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSemaglutide, liraglutide and tirzepatide are glucagon-like peptide-1 (GLP-1) receptor agonists that are effective for weight reduction. Recent reports of patients experiencing suicidal thoughts and other psychiatric adverse events while using GLP-1 agonists have raised concerns about the potential risk of self-harm and led the European Medicines Agency to investigate these medications.

aimTo identify and analyse the psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide.

methodAll individual case safety reports for semaglutide, liraglutide, and tirzepatide reported to the EudraVigilance database from 01/01/2021 to 30/05/2023 were analysed. Descriptive statistics were used to explore study population characteristics.

resultsDuring the study period, 31,444 adverse event reports were identified: semaglutide (n = 13,956; 44.4%), liraglutide (n = 16,748; 53.2%), and tirzepatide (n = 740; 2.3%). There were 372 reports with psychiatric adverse event reports (n = 372; 1.18%) with a total of 481 adverse events. Women accounted for 65% (n = 242) of these reports. Depression was the most commonly reported adverse event (n = 187; 50.3%), followed by anxiety (n = 144; 38.7%) and suicidal ideation (n = 73; 19.6%). Nine deaths (8 with liraglutide and 1 with semaglutide) and 11 life-threatening outcomes (4 associated with liraglutide and 7 with semaglutide) were reported. The fatal outcomes occurred primarily among men (8 out of 9) resulting from completed suicidal attempts and depression.

conclusionPsychiatric adverse events comprised only 1.2% of the total reports for semaglutide, liraglutide, and tirzepatide. However, the severity and fatal outcomes of some of these reports warrant further investigation.

Indexed as

Diabetes Mellitus, Type 2Gastric Inhibitory PolypeptideGlucagon-Like Peptide-2 ReceptorGlucagon-Like PeptidesLiraglutideFemaleGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsHumansHypoglycemic AgentsMalePharmacovigilanceSemaglutideTirzepatideGastric Inhibitory PolypeptideGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-2 ReceptorGlucagon-Like PeptidesHypoglycemic AgentsLiraglutideSemaglutideTirzepatideLiraglutideObesityPsychiatric adverse eventsSemaglutideSuicideTirzepatide

Identifiers

PMID38265519
PMCPMC10960895
OpenAlexW4391170552

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.